Genmab and Seagen submit cancer drug application to US FDA

The US FDA will evaluate a cervical cancer treatment developed by Genmab and Seagen

Photo: Joost Melis / Genmab / PR

Danish biotech firm Genmab and US biotech firm Seagen have applied for an accelerated approval of the drug candidate tisotumab vedotin at the US Food and Drug Administration, according to a Genmab press release on Wednesday.

Tisotumab vedotin has been proclaimed as one of Genmab's future pipeline hopes. The firm shares ownership of tisotumab vedotin with the US biotech firm Seagen, which used to go by the name Seattle Genetics.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs